Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II clinical trial of pazopanib with unresectable or metastatic malignant peripheral nerve sheath tumor (1st cohort) and in patients with chemoresistant tumors; alveolar soft part sarcoma, epithelioid sarcoma, and clear cell sarcoma (2nd cohort)

Trial Profile

Phase II clinical trial of pazopanib with unresectable or metastatic malignant peripheral nerve sheath tumor (1st cohort) and in patients with chemoresistant tumors; alveolar soft part sarcoma, epithelioid sarcoma, and clear cell sarcoma (2nd cohort)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Alveolar soft part sarcoma; Clear cell sarcoma; Nerve sheath neoplasms; Sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2022 Planned End Date changed from 31 Aug 2019 to 14 Jan 2023.
    • 01 Sep 2020 Results assessing effect of pazopanib on chemoresistant sarcomas (ASPS, ES, and CCS) from Cohort 2 of this study published in the Cancer Science
    • 31 May 2020 Status changed from active, no longer recruiting to completed according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top